TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals presented preclinical data at the 64th ACNP Annual Meeting showing that OX2R activation with their agonist CNT-9982 reduced behavioral despair and enhanced wakefulness in animal models of major depressive disorder. The company plans to expand its OX2R agonist pipeline beyond rare hypersomnias into additional neuropsychiatric indications with high unmet clinical need.

Insights
META   neutral

Mentioned in market movers list but no specific analysis provided in the article


CNTA   positive

The company announced promising preclinical data supporting expansion of its OX2R agonist pipeline into new neuropsychiatric indications. The results demonstrate antidepressive effects and enhanced wakefulness, supporting the therapeutic potential of their drug candidates. The company is advancing its clinical development strategy with Phase 2a trials underway and plans to explore high-value indications with significant unmet clinical needs.